Jazz Pharmaceuticals (JAZZ) Misses Q2 EPS by 17c; Issues Mixed Outlook

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $2.63, $0.17 worse than the analyst estimate of $2.80. Revenue for the quarter came in at $381 million versus the consensus estimate of $376.42 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2016 EPS of $9.90-$10.30, versus the consensus of $11.14. Jazz Pharmaceuticals sees FY2016 revenue of $1.485-1.53 billion, versus the consensus of $1.52 billion.

"We have made significant progress in 2016, as we continue to build the foundation for future growth by further diversifying and strengthening our hematology/oncology portfolio with the addition of Vyxeos, a late-stage product candidate for the treatment of acute myeloid leukemia, through the acquisition of Celator Pharmaceuticals," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "We achieved strong organic sales growth of our key products, including a significant contribution from the U.S. launch of Defitelio, received FDA approval of our manufacturing facility in Athlone, Ireland and entered into additional corporate development transactions with the potential to bring innovative treatment options to patients."

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• WWP, Plc (WPP) Issues Q1 Trading Update
• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition